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Abstract
Using glutathione S-transferase Syk fusion proteins, we evaluated the mode of platelet FcQRII tyrosine phosphorylation
induced by FcQRII cross-linking or anti-CD9 monoclonal antibodies (mAb). The N-terminal SH2 domain of Syk (Syk-N-
SH2), the C-terminal SH2 domain of Syk (Syk-C-SH2), and the domain having both the N- and C-terminal SH2 of Syk (Syk-
NC-SH2) all bound to tyrosine-phosphorylated FcQRII with FcQRII cross-linking. In the case of anti-CD9 mAb-induced
platelet activation, only Syk-C-SH2 and Syk-NC-SH2 bound to tyrosine-phosphorylated FcQRII. Since the SH2 domain is
specific for a particular structure containing phosphotyrosine, these findings suggest that only one tyrosine residue in the
immunoreceptor tyrosine-based activation motif (ITAM) is phosphorylated with anti-CD9 mAb, and that both are
phosphorylated with FcQRII cross-linking. Synthetic peptides corresponding to the ITAM of human platelet FcQRII with the
N-terminal tyrosine residue phosphorylated (N-P) or the C-terminal tyrosine residue phosphorylated (C-P), were used. N-P
more potently dissociated Syk-C-SH2 from tyrosine-phosphorylated FcQRII than C-P, suggesting that the N-terminal
tyrosine residue is phosphorylated upon anti-CD9 mAb-induced activation. Furthermore, these findings imply that Syk-N-
SH2 binds to the phosphorylated C-terminal tyrosine residue of ITAM, and Syk-C-SH2 to the N-terminal tyrosine. Taken
together, our findings suggest that FcQRII-dependent platelet activation without FcQRII dimerization, such as with anti-CD9
mAb, is distinct from that induced by FcQRII cross-linking. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
While there are several Fc receptor subtypes for
IgG, human platelets express only the low a⁄nity
Fc receptor for IgG, FcQRII [1,2]. FcQRII cross-link-
ing induces platelet activation that involves several
signaling events, including Ca2 mobilization and ty-
rosine phosphorylation of FcQRII [3^7]. Fc receptor
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tyrosine phosphorylation appears to be an early and
essential event in Fc receptor-mediated signaling.
The intracytoplasmic domain of FcQRII contains a
single copy of an activation motif termed ‘immuno-
receptor tyrosine-based activation motif’ (ITAM)
[8,9]. This motif is present in signaling subunits of
the T-cell antigen receptor, the B-cell antigen recep-
tor, and the high a⁄nity IgE receptor (FcORI) [10^
13]. The atypical ITAM of platelet FcQRII has 12
amino acids between two YXXL boxes, rather than
the 7 amino acids found in ordinary ITAM [14,15].
Upon platelet activation mediated by FcQRII cross-
linking, the tyrosine residues in ITAM are phos-
phorylated. Subsequently, Syk, a tyrosine kinase
with two SH2 domains, associates with the tyro-
sine-phosphorylated ITAM [16^18]. Since Syk with
two SH2 domains binds to tyrosine-phosphorylated
FcQRII, it has been suggested that both tyrosine res-
idues of FcQRII are phosphorylated in FcQRII cross-
linking-induced platelet activation, although there
has been no direct evidence for this hypothesis.
The CD9 antigen is a cell surface molecule with a
molecular mass of 24 kDa expressed in platelets as
well as other cells [19]. Although the potential role of
CD9 in the regulation of cell growth has been pro-
posed in other cells [20], its precise function remains
unknown in platelets, which lack the ability to pro-
liferate. Anti-CD9 monoclonal antibodies (mAbs)
are potent agonists that activate platelets, causing
aggregation and a [Ca2]i rise [21,22]. Since IV.3,
an anti-FcQRII mAb which blocks FcQRII, also in-
hibits anti-CD9 mAb-mediated platelet activation
[23], the major mechanism of platelet activation ap-
pears to be FcQRII-dependent. Anti-CD9 mAbs also
induce FcQRII tyrosine phosphorylation, similar to
FcQRII cross-linking. Hence, the pro¢le of platelet
activation induced by anti-CD9 mAbs is thought to
be similar to that induced by FcQRII cross-linking.
However, recent studies have demonstrated that
platelet activation induced by anti-CD9 mAbs, which
does not cause FcQRII dimerization, is distinct in
some aspects from that of FcQRII cross-linking
which does cause FcQRII dimerization [7,24]. Ca2
in£ux induced by FcQRII cross-linking depended
upon Ca2 depletion of intracellular Ca2 stores,
whereas anti-CD9 mAbs induced Ca2 in£ux by di-
rectly activating the Ca2 channel. Piceatannol, a
selective inhibitor of Syk, potentiated FcQRII tyro-
sine phosphorylation with FcQRII cross-linking, but
attenuated that of anti-CD9 mAbs. The tyrosine ki-
nases, Lyn and Syk, associated with FcQRII upon
platelet activation induced by FcQRII cross-linking,
yet did not do so with anti-CD9 mAb [24].
Syk is known to interact with the phosphorylated
tyrosine residues of ITAM in the cytoplasmic tail of
FcQRII [16,17]. Although both anti-CD9 mAbs and
FcQRII cross-linking led to Syk activation and tyro-
sine phosphorylation of FcQRII, we found in our
previous study that the association of Syk with
FcQRII occurred only with FcQRII cross-linking
[24]. Based on these ¢ndings, we suggest that there
are some other molecules that link Syk activation
with tyrosine-phosphorylated FcQRII and that the
pro¢le of ITAM tyrosine phosphorylation di¡ers be-
tween these two modes of platelet activation. To in-
vestigate this di¡erence further, we evaluated the in-
teraction of FcQRII with glutathione S-transferase
(GST) fusion proteins expressing one or both of
the N-terminal and C-terminal SH2 domains of
Syk (Syk-NC-SH2, Syk-N-SH2, and Syk-C-SH2).
We also examined inhibition by each synthetic pep-
tide corresponding to ITAM in the association be-
tween FcQRII and these GST fusion proteins.
2. Materials and methods
2.1. Materials
The following materials were obtained from the
indicated suppliers: PGI2 (Funakoshi, Tokyo, Ja-
pan); leupeptin and BSA (Sigma, St. Louis, MO,
USA); anti-FcQRII mAb (IV.3) (Medarax, West Leb-
anon, NH, USA); anti-FcQRII mAb (2E1) (Immuno-
tech, Marseille, France); anti-phosphotyrosine mAb
(4G10) (Upstate Biotechnology, Lake Placid, NY,
USA); mouse IgG standard and anti-Syk mAb
(Wako, Tokyo, Japan). Peptides corresponding to
the ITAM of human FcQRII were purchased from
Sawaday Technology (Tokyo, Japan). NNKY 1-19
(anti-CD9 mAb), NNKY 3-2 (anti-FcQRII mAb),
and PMA-4 (an anti-GPIIb/IIIa mAb), were ob-
tained by immunizing mice with human platelets
[25^27].
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2.2. Preparation of human platelets
Venous blood was drawn from drug-free volun-
teers and added to a citric acid-citrate-dextrose
base. Platelet-rich plasma obtained after centrifuga-
tion at 160Ug for 10 min was incubated with 1 mM
of acetylsalicylate for 30 min to exclude the secon-
dary e¡ects of thromboxane A2. The platelets were
washed and resuspended in a bu¡er containing 138
mM NaCl, 3.3 mM NaH2PO4, 2.9 mM KCl, 1 mM
MgCl2, 1 mg/ml glucose, and 20 mM HEPES (pH
7.4). The ¢nal platelet suspensions were adjusted to a
concentration of 1U109 cells/ml.
2.3. Immunoprecipitation of FcQRII and detection of
its tyrosine phosphorylation
Platelets were activated by 20 Wg/ml of NNKY 1-
19 (an anti-CD9 mAb), 20 Wg/ml of PMA-4 (an anti-
GPIIb/IIIa mAb), or by FcQRII cross-linking.
FcQRII cross-linking was achieved by treating plate-
lets with 10 Wg/ml of IV.3, an anti-FcQRII mAb, for
30 s, followed by the addition of 50 Wg/ml of F(abP)2
fragment anti-mouse IgG mAb.
After platelets were activated for various periods
of time, reactions were terminated with the addition
of an equal volume of ice-cold lysis bu¡er (2% Triton
X-100, 100 mM Tris/HCl, pH 7.2, 50 mM NaCl,
5 mM EDTA, 2 mM vanadate, 1 mM PMSF, and
100 Wg/ml of leupeptin). The samples were then so-
nicated and subjected to centrifugation at 16 000Ug
for 5 min. The supernatant was precleared with
CNBr glycine-Sepharose beads for 30 min. In the
case of anti-CD9 mAb- or PMA-4-induced platelet
activation, anti-FcQRII mAb bound to CNBr-acti-
vated Sepharose beads was then added to the super-
natant. To the supernatants of platelets activated by
FcQRII cross-linking, protein A-Sepharose beads
were added. After the mixture was rotated for 2 h
at 4‡C, the Sepharose beads were washed three times
with lysis bu¡er and once with HEPES bu¡er. Fi-
nally, 50 Wl of HEPES bu¡er and 25 Wl of Laemmli
bu¡er were added to the beads and proteins were
eluted by boiling for 3 min. Proteins were separated
by SDS-PAGE (8%) under reducing conditions, and
transferred to a Clear Blot Membrane-P (Atto). De-
tection of FcQRII tyrosine phosphorylation was per-
formed by Western blotting using an anti-phospho-
tyrosine mAb, 4G10.
2.4. Preparation of GST fusion proteins encoding the
SH2 domains of Syk
For the generation of GST fusion proteins con-
taining the SH2 domains of Syk, PCR was used to
amplify cDNAs encoding one or both SH2 domains
of Syk using the following pairs of primers. GST-
Syk-NC-SH2 (5P primer, 5P-GCG GGA TCC AGC
GCC AAC CAC CRG CCC-3P ; 3P primer, 5P-GCG
GAA TTC TCA GCC GAT TTT TTG ACA TGG-
3P). GST-Syk-N-SH2 (5P primer, 5P-GCG GGA TCC
AGC GCC AAC CAC CRG CCC-3P ; 3P primer, 5P-
GCG GAA TTC CTT GGG CCG GTT GAA
GGG-3P). GST-Syk-C-SH2 (5P primer, 5P-GCG
GGA TCC GAT GAA AAA ATG CCT TGG-3P ;
3P primer, 5P-GCG GAA TTC TCA GCC GAT TTT
TTG ACA TGG-3P). Underlined nucleotides repre-
sent BamHI and EcoRI sites in the 5P and 3P primers,
respectively. The PCR products were then cut with
these enzymes and ligated into BamHI-EcoRI cut
pGEX-2T (Pharmacia LKB Biotechnology, Piscat-
away, NJ, USA). Plasmids encoding GST fusion pro-
teins containing either one or both SH2 domains of
Syk were transferred into the Escherichia coli strain
BL21 [28], and then the fusion proteins were puri¢ed
from isopropyl L-D-thiogalactoside-induced bacteria
with glutathione Sepharose beads (Pharmacia To-
kyo, Japan).
2.5. Analysis of proteins coprecipitated with SH2
domains of Syk
Platelets were activated by various mAbs, as de-
scribed above, then reactions were terminated by the
addition of an equal volume of ice-cold lysis bu¡er.
After sonication and 30 min preclearing with gluta-
thione beads, the lysates were incubated with 20 Wg
of GST fusion proteins expressing either the Syk
N-terminal SH2 domain (Syk-N-SH2), Syk C-termi-
nal SH2 domain (Syk-C-SH2) or both the N- and
C-terminal SH2 domains (Syk-NC-SH2) for 2 h.
Glutathione beads were then added to the mixture
to collect proteins associated with GST fusion pro-
teins, and mixing was continued for another hour at
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4‡C. The glutathione beads were washed 3 times with
lysis bu¡er and once with 10 mM HEPES (pH 8.0),
before the addition of Laemmli sample bu¡er. Pro-
teins were separated by 8% SDS-PAGE and trans-
ferred to a Clear Blot Membrane-P (Atto). Western
blotting was then performed using an anti-phospho-
tyrosine mAb, 4G10.
2.6. E¡ects of tyrosine-phosphorylated peptides
corresponding to ITAM on the association
between FcQRII and GST fusion proteins
expressing Syk SH2 domains
Platelets were activated by NNKY 1-19, PMA-4
or FcQRII cross-linking for 2 min, and reactions
were terminated by the addition of an equal volume
of ice-cold lysis bu¡er as described above. After
30 min of preclearing with glutathione beads, the
lysates were separated from the beads by centrifuga-
tion at 12 000Ug for 2 min. Various concentrations
of the peptides and GST fusion proteins expressing
the Syk SH2 domains were added to the superna-
tants. The mixtures were rotated for 2 h and after
the addition of glutathione beads, rotation was con-
tinued for another hour at 4‡C. The glutathione
beads were washed 3 times with lysis bu¡er and
once with HEPES bu¡er. Finally, 50 Wl of HEPES
bu¡er and 25 Wl of Laemmli bu¡er were added, and
the mixture was subjected to 8% SDS-PAGE and
Western blotting, as described above.
3. Results
3.1. Evidence for the association between Syk SH2
domains and tyrosine-phosphorylated FcQRII
We ¢rst sought to con¢rm that GST fusion pro-
teins expressing either Syk-NC-SH2, Syk-C-SH2, or
Syk-N-SH2 coprecipitated with tyrosine-phosphoryl-
ated FcQRII. After platelet activation induced by
FcQRII cross-linking, platelets were lysed, and incu-
bated with Syk GST fusion proteins. Coprecipitates
of Syk GST fusion proteins were analyzed with
Western blotting for the presence of FcQRII. When
4G10, a mAb against phosphotyrosine, was used for
Western blotting, Syk-N-SH2 and Syk-C-SH2 copre-
cipitated a major band of 40 kDa (lanes 4 and 6, Fig.
1), while Syk-NC-SH2 coprecipitated a number of
tyrosine-phosphorylated proteins including the 40,
60, 64 and 75 kDa proteins (lane 2, Fig. 1). The
48 kDa band in lane 2 was the non-speci¢c staining
of Syk-NC-SH2 itself. Since none of the mAbs
against FcQRII available today (IV.3, 2E1, or
NNKY 3-2) are suitable for Western blotting, we
performed a ‘depletion’ experiment. When platelet
lysates were ¢rst incubated with Sepharose beads
coated with anti-FcQRII mAb, IV.3 to remove
FcQRII, the major band of 40 kDa which coprecipi-
tated with Syk-C-SH2 or Syk-N-SH2 was markedly
attenuated (lanes 3 and 5, Fig. 1). With Syk-NC-
SH2, the 40 kDa band was reduced by 82% (means
of two experiments), while the other bands were vir-
tually una¡ected (lane 1, Fig. 1). These ¢ndings con-
¢rm that the 40 kDa protein was tyrosine-phos-
phorylated FcQRII.
We then performed competitive inhibitory tests us-
ing peptides corresponding to the ITAM to further
con¢rm that the 40 kDa protein was tyrosine-phos-
phorylated FcQRII. Brie£y, two synthetic peptides
Fig. 1. Association of tyrosine-phosphorylated FcQRII with
GST fusion proteins expressing Syk SH2 domains. Platelets
were activated by FcQRII cross-linking, as described in Section
2, and reactions terminated by adding lysis bu¡er. The lysates
were then split into two portions, and one portion was pre-
cleared twice with Sepharose beads. The other half was ¢rst
precleared with Sepharose beads, then incubated with protein
A-Sepharose beads to remove FcQRII. After centrifugation, the
supernatants were incubated with GST Syk fusion proteins and
the coprecipitates were analyzed with Western blotting using an
anti-phosphotyrosine mAb, 4G10. Lanes: 1 and 2, Syk-NC-
SH2; 3 and 4, Syk-N-SH2; 5 and 6, Syk-C-SH2. Lanes 2, 4
and 6 represent the coprecipitates which were precleared only
with Sepharose beads, and lanes 1, 3 and 5 represent those
from which the FcQRII was removed.
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corresponding to the ITAM of FcQRII were synthe-
sized. One peptide had its two tyrosine residues phos-
phorylated (lane 2, Fig. 2A), and in the other pep-
tide, the two tyrosine residues were left
unphosphorylated (lane 1, Fig. 2A). When added to
the coprecipitation step, the non-phosphorylated
peptide, even at a concentration of 200 WM, failed
to inhibit the association of Syk-NC-SH2 with the
tyrosine-phosphorylated 40 kDa (lane 5, Fig. 2B),
whereas the phosphorylated peptide inhibited in a
dose-dependent manner (12.5^200 WM) the associa-
tion between Syk-NC-SH2 and the 40 kDa protein
(lanes 6^8, Fig. 2B). These ¢ndings suggest that the
binding between Syk GST fusion proteins and
FcQRII is indeed mediated by the tyrosine phospho-
rylation of ITAM.
3.2. Di¡erential binding of Syk SH2 domains with
tyrosine-phosphorylated FcQRII induced by
FcQRII cross-linking or anti-CD9 mAb
Previous studies have shown that Syk associates
with tyrosine-phosphorylated FcQRII upon platelet
activation induced by FcQRII cross-linking, but not
in the case of anti-CD9 mAb-induced platelet activa-
tion. To clarify the cause of this discrepancy, we
evaluated the di¡erences in the binding pro¢le of
Syk GST fusion proteins with tyrosine-phosphoryl-
ated FcQRII between FcQRII cross-linking, and anti-
CD9 mAb-induced platelet activation.
Platelets were activated either by FcQRII cross-
linking or by NNKY 1-19 (20 Wg/ml), an anti-CD9
mAb, for 5 min. The reactions were then terminated
with lysis bu¡er, and the coprecipitated tyrosine-
phosphorylated FcQRII with Syk GST fusion pro-
teins was analyzed with Western blotting using
4G10. Syk-NC-SH2, Syk-N-SH2 and Syk-C-SH2 co-
precipitated with tyrosine-phosphorylated FcQRII,
respectively, in platelet activation induced by FcQRII
cross-linking (lanes 6^8, Fig. 3). Syk-NC-SH2 most
actively precipitated FcQRII, while densitometric
analysis revealed that the amount of tyrosine-phos-
phorylated FcQRII associated with Syk-C-SH2 was
almost equal to that of Syk-N-SH2 (1.2 times).
Fig. 2. (A) Synthetic peptides corresponding to ITAM. Under-
lined letters represent the phosphorylated tyrosine residues. (1)
The peptide sequence corresponding to unphosphorylated
ITAM. (2) The peptide sequence in ITAM with both tyrosines
phosphorylated. (B) Inhibitory e¡ect of peptides corresponding
to ITAM on the binding of Syk-NC-SH2 to FcQRII. Platelets
were activated with FcQRII cross-linking, then reactions were
terminated by adding lysis bu¡er. After preclearing, the lysates
were incubated with Syk-NC-SH2 in the presence of various
concentrations of ITAM peptides, and the coprecipitates of
Syk-NC-SH2 were analyzed with Western blotting using anti-
phosphotyrosine mAb. Lanes: 3, the coprecipitate of GST with-
out fusion proteins as a control; 4, Syk-NC-SH2 in the absence
of peptides; 5, Syk-NC-SH2 in the presence of 200 WM of non-
phosphorylated ITAM peptide; 6, Syk-NC-SH2 in the presence
of 12.5 WM of the peptide with two tyrosine residues phos-
phorylated; 7, the same as lane 6 but with 50 WM of the pep-
tide; 8, the same as lane 6 but with 200 WM of the peptide.
Lanes 1 and 2 represent the immunoprecipitate of FcQRII in
the resting platelets, and in platelets activated by FcQRII cross-
linking.
Fig. 3. Association between tyrosine-phosphorylated FcQRII
and various GST fusion proteins expressing Syk SH2 domains.
Platelets were stimulated by NNKY 1-19, an anti-CD9 mAb
(20 Wg/ml), for 5 min (lanes 1^4) or by FcQRII cross-linking
(lanes 5^8). Reactions were terminated by adding a lysis bu¡er,
and after preclearing the coprecipitates of Syk-N-SH2, Syk-C-
SH2, or Syk-NC-SH2 were analyzed with Western blotting us-
ing an anti-phosphotyrosine mAb, 4G10. Lanes: 1 and 5, GST;
2 and 6, GST-Syk-NC-SH2; 3 and 7, GST-Syk-N-SH2; 4 and
8, GST-Syk-C-SH2.
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Syk-NC-SH2 and Syk-C-SH2 coprecipitated with
tyrosine-phosphorylated FcQRII in platelet activation
induced by anti-CD9 mAb (lanes 2 and 4, Fig. 3),
whereas Syk-N-SH2 only weakly coprecipitated with
tyrosine-phosphorylated FcQRII (lane 3, Fig. 3). To
con¢rm that there was a qualitative di¡erence in the
mode of association between Syk-SH2 GST fusion
proteins and FcQRII, we used a high concentration
of anti-CD9 mAb (200 Wg/ml), which was 10 times
higher than the optimal concentration. The results
were essentially the same as those for 20 Wg/ml of
anti-CD9 mAb (data not shown). The densitometric
analysis revealed that the amount of tyrosine-phos-
phorylated FcQRII associated with Syk-C-SH2 was
6.0 times greater than that of Syk-N-SH2.
3.3. Tyrosine phosphorylation of FcQRII induced by
PMA-4 and association between the Syk SH2
domains and FcQRII
Based on our previous results, we then considered
whether these di¡erences could be attributed to the
presence or absence of FcQRII dimerization, or to a
speci¢c property of anti-CD9 mAb-induced platelet
activation. To address this issue, we evaluated the
e¡ects of another mAb, PMA-4, which induces plate-
let activation in an FcQRII-dependent manner [27].
PMA-4 is directed against GPIIb/IIIa on the platelet
membrane, and its F(abP)2 fragments, although to a
limited degree, induce the opening of ¢brinogen
binding sites in GPIIb/IIIa without intracellular
Ca2 mobilization, the release of intracellular gran-
ule contents, or protein tyrosine phosphorylation
[31]. PMA-4, at a concentration of 20 Wg/ml, induced
tyrosine phosphorylation of the 75 kDa and 64 kDa
proteins in platelets, similar to anti-CD9 mAb or
FcQRII cross-linking (data not shown). It also in-
duced tyrosine phosphorylation of FcQRII as early
as 15 s after platelet activation (Fig. 4A). We then
evaluated the binding patterns of the GST fusion
proteins expressing Syk SH2 domains with tyrosine-
phosphorylated FcQRII induced by PMA-4. As with
anti-CD9 mAb, Syk-NC-SH2 and Syk-C-SH2 copre-
cipitated with tyrosine-phosphorylated FcQRII (lanes
2 and 4, Fig. 4B), whereas the FcQRII which copre-
cipitated with Syk-N-SH2 was only barely detectable
(lane 3, Fig. 4B). These ¢ndings are similar to those
of anti-CD9 mAb, and distinct from those of FcQRII
cross-linking, in which all Syk SH2 domains bind to
tyrosine-phosphorylated FcQRII.
3.4. Competitive inhibitory e¡ects of synthetic
peptides corresponding to ITAM on the binding
of Syk SH2 domains to FcQRII
The results hitherto have suggested that only one
tyrosine residue of ITAM is phosphorylated in anti-
CD9 mAb- or PMA-4-induced platelet activation, to
which Syk-C-SH2 is able to bind. It was of interest
to ¢nd out which tyrosine residue in ITAM, the
N-terminal or C-terminal, is phosphorylated. To ad-
dress this issue, we produced two synthetic peptides
corresponding to ITAM, whose N-terminal or C-ter-
minal tyrosine residue was phosphorylated (ETA-
DGGYMTLNPRAPTDDDKNIYLTLPPN, termed
Fig. 4. (A)Tyrosine phosphorylation of FcQRII induced by
PMA-4. Platelets were stimulated by PMA-4, an anti-GPIIb/
IIIa mAb (20 Wg/ml) for the indicated period of time, and reac-
tions terminated by adding a lysis bu¡er. Then, FcQRII was im-
munoprecipitated with IV.3, an anti-FcQRII mAb, bound to
CNBr-Sepharose beads. The samples were separated by an 8%
SDS-PAGE, and Western blotted to assay for tyrosine-phos-
phorylated proteins, using 4G10. The data are representative of
three experiments. (B) Association of GST fusion proteins ex-
pressing Syk SH2 domains with tyrosine-phosphorylated FcQRII
induced by PMA-4. Platelets were stimulated by PMA-4 (20 Wg/
ml) for 5 min and reactions terminated by the addition of a ly-
sis bu¡er. GST fusion proteins expressing Syk SH2 domains
were then added to the lysates, and 2 h later, proteins associ-
ated with GST fusion proteins were collected by the addition of
glutathione beads. The samples were separated by an 8% SDS-
PAGE, and Western blotted for tyrosine phosphorylation, using
4G10. Lanes: 1, GST; 2, Syk-NC-SH2; 3, Syk-N-SH2; 4, Syk-
C-SH2. The data are representative of three experiments.
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as ‘N-P’, and ETADGGYMTLNPRAPTDDDKNI-
YLTLPPN termed as ‘C-P’). The underlined letters
represent the phosphorylated tyrosine residues. Plate-
lets were ¢rst activated by anti-CD9 mAb or PMA-4
for 5 min, then various concentrations of synthetic
peptide (N-P or C-P) and Syk-C-SH2 were copre-
cipitated to evaluate the binding of tyrosine-phos-
phorylated FcQRII to Syk-C-SH2. As shown in Fig.
5A, N-P, even at a concentration of 2 WM, e¡ectively
inhibited the association between Syk-C-SH2 and ty-
rosine-phosphorylated FcQRII (at 10 WM the inhibi-
tory e¡ect was almost complete) when platelets were
activated with anti-CD9 mAb. The inhibitory e¡ect
of C-P was much weaker than that of N-P (Fig. 5A).
The densitometric analysis of the dissociation rate is
shown in Fig. 5B. The results with PMA-4 were es-
sentially the same as those of anti-CD9 mAb (data
not shown).
Our ¢nding that Syk-C-SH2 preferentially binds to
the phosphorylated N-terminal tyrosine residue on
ITAM provides a model for Syk binding to tyro-
sine-phosphorylated FcQRII, such as seen with
FcQRII cross-linking. To con¢rm this hypothesis,
Fig. 6. Inhibitory e¡ects of synthetic tyrosine-phosphorylated
peptides on the association of tyrosine-phosphorylated FcQRII,
with Syk-N-SH2 or Syk-C-SH2, in FcQRII cross-linking-induced
platelet activation. Platelets were activated with FcQRII cross-
linking for 2 min, then reactions were terminated by adding a
lysis bu¡er. After preclearing, the lysates were incubated with
various concentrations of synthetic tyrosine-phosphorylated
peptides and Syk-N-SH2 or Syk-C-SH2 for 3 h. The samples
were Western blotted with 4G10, to detect the association of
FcQRII with Syk-N-SH2 or Syk-C-SH2. (A) Syk-N-SH2; (B)
Syk-C-SH2. The data are representative of four experiments.
N-P refers to the peptide with N-terminal tyrosine residue phos-
phorylated; C-P refers to the peptide with C-terminal tyrosine
residue phosphorylated.
Fig. 5. (A) Competitive inhibitory e¡ects of synthetic tyrosine-
phosphorylated peptides on the association between the FcQRII
and Syk-C-SH2 domains induced by anti-CD9 mAb. Platelets
were activated with anti-CD9 mAb for 5 min, then reactions
were terminated by adding a lysis bu¡er. The samples were in-
cubated with Syk-C-SH2 and various concentrations of syn-
thetic tyrosine-phosphorylated peptides for 3 h. The association
between tyrosine-phosphorylated FcQRII and Syk-C-SH2 was
evaluated with Western blotting, using 4G10. N-P refers to the
peptide with N-terminal tyrosine residue phosphorylated; C-P
refers to the peptide with C-terminal tyrosine residue phos-
phorylated. The data are representative of four experiments. (B)
Densitometric analysis of the inhibitory e¡ects of phosphoryl-
ated ITAM peptides on the association between tyrosine-phos-
phorylated FcQRII and Syk-C-SH2 in platelet activation in-
duced by anti-CD9 mAb. R, N-P; F, C-P. The data represent
the means þ S.E. of four experiments.
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we evaluated the competitive inhibitory e¡ects of N-
P or C-P on the association of tyrosine-phospho-
rylated FcQRII with Syk-C-SH2 or Syk N-SH2 in
FcQRII cross-linking. N-P at a concentration of 250
WM only slightly inhibited the association between
tyrosine-phosphorylated FcQRII and Syk-N-SH2,
whereas C-P at 50 WM attenuated it slightly, and a
concentration of 250 WM almost completely inhibited
the binding of Syk-N-SH2 to tyrosine-phospho-
rylated FcQRII (Fig. 6A). In contrast, C-P, even at
a concentration of 250 WM, had a limited inhibitory
e¡ect on the binding of Syk-C-SH2 to tyrosine-phos-
phorylated FcQRII. N-P at a concentration of 250
WM completely inhibited the association between
Syk-C-SH2 and tyrosine-phosphorylated FcQRII
(Fig. 6B). The densitometric analysis of the dissoci-
ation rate is shown in Fig. 7. Thus, C-P preferentially
dissociates Syk-N-SH2 from FcQRII and N-P from
Syk-C-SH2.
4. Discussion
Syk, a tyrosine kinase with two SH2 domains, is
known to bind to tyrosine-phosphorylated FcQRII.
More speci¢cally, Syk with its two SH2 domains
binds to a motif termed ‘ITAM’ present in the cyto-
plasmic domain of FcQRII, when the tyrosine resi-
dues in ITAM are phosphorylated [16^18]. In pre-
vious studies, we found that Syk was associated
with tyrosine-phosphorylated FcQRII in FcQRII
cross-linking-induced platelet activation, whereas in
anti-CD9 mAb-induced platelet activation there was
no association between Syk and tyrosine-phosphoryl-
ated FcQRII. In the present study, we sought to elu-
cidate the mechanism underlying this discrepancy.
Using GST fusion proteins expressing Syk SH2 do-
mains, we found that tyrosine-phosphorylated
FcQRII binds to Syk-C-SH2 more strongly than
Syk-N-SH2 (6-fold as determined by densitometry)
in anti-CD9 mAb-induced platelet activation, where-
as there was only a slight di¡erence between Syk-C-
SH2 and Syk-N-SH2 in their binding to tyrosine-
phosphorylated FcQRII with FcQRII cross-linking
(1.2-fold as determined by densitometry). Previous
reports have suggested that the binding capacity of
Syk-N-SH2 is weaker than that of Syk-C-SH2, since
the binding structure of Syk-N-SH2 may not be com-
plete without the involvement of part of Syk-C-SH2
[29]. However, since our ¢ndings on the FcQRII as-
sociation with Syk-N-SH2 or Syk-C-SH2 in FcQRII
cross-linking have revealed that the binding capacity
of Syk-C-SH2 is almost equal to Syk-N-SH2, this
hypothesis cannot completely explain the large di¡er-
ence between the binding capacities of Syk-N-SH2
and Syk-C-SH2 in the case of anti-CD9 mAb-in-
duced platelet activation.
The SH2 domains recognize a tyrosine-phospho-
rylated site and adjacent structure, rendering its
binding speci¢c to a certain structure containing
phosphotyrosine [30]. Thus, it is likely that Syk-C-
SH2 recognizes a site distinct from that of Syk-N-
SH2. Based on this concept and our ¢ndings in these
experiments, we assumed that phosphorylation oc-
curs only on one tyrosine residue of FcQRII ITAM
when platelets are activated by anti-CD9 mAb, to
which Syk-N-SH2 only weakly binds. The a⁄nity
of Syk for ITAM with a single phosphorylated tyro-
sine residue is much lower than that for ITAM with
Fig. 7. Densitometric analysis of the inhibitory e¡ects of ITAM
peptides on the association of Syk SH2 domains with tyrosine-
phosphorylated FcQRII in platelet activation induced by FcQRII
cross-linking. R, N-P; F, C-P. The data represent the mean-
s þ S.E. of four experiments. (A) Inhibitory e¡ects of ITAM
peptides on the association of Syk-N-SH2 with tyrosine-phos-
phorylated FcQRII. (B) Inhibitory e¡ects of ITAM peptides on
the association of Syk-C-SH2 with tyrosine-phosphorylated
FcQRII. The data represent the means þ S.E. of four experi-
ments.
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two phosphorylated tyrosine residues [32], providing
evidence for our previous ¢nding that Syk did not
coprecipitate with tyrosine-phosphorylated FcQRII in
anti-CD9 mAb-induced platelet activation [24]. In
order to con¢rm this hypothesis, we then used pep-
tides corresponding to ITAM which were either
C- (C-P) or N-terminal tyrosine (N-P) phosphoryl-
ated. N-P more potently inhibited the binding of
Syk-C-SH2 to tyrosine-phosphorylated FcQRII than
C-P (Fig. 5). Although C-P at high concentrations
slightly inhibited the binding, this e¡ect was most
likely due to the non-speci¢c e¡ect of the tyrosine-
phosphorylated peptides. Based on these ¢ndings, we
suggest that the N-terminal tyrosine residue in
FcQRII ITAM, but not the C-terminal, is phospho-
rylated with anti-CD9 mAb-induced platelet activa-
tion. These ¢ndings were the same with PMA-4, an
anti-GPIIb/IIIa mAb which activates platelets via
FcQRII [31]. Thus, it is likely that platelet-activating
antibodies such as anti-CD9 mAbs elicit certain in-
tracellular signals distinct from FcQRII cross-linking,
which induces FcQRII dimerization. There is another
tyrosine residue without the YxxL structure in the
cytoplasmic domain of FcQRII. We cannot com-
pletely rule out the possibility that this tyrosine res-
idue is also phosphorylated. However, based upon
competitive inhibition studies using the ITAM pep-
tide, and the active binding of the Syk-SH2 domain
to YxxL, we assume that its possible involvement in
Syk binding is remote in FcQRII-related platelet ac-
tivation.
Our ¢ndings also suggest that both of the tyrosine
residues in ITAM are phosphorylated in FcQRII
cross-linking-induced platelet activation. In peptide
inhibition experiments, we found that N-P more
strongly dissociated Syk-C-SH2 with tyrosine-phos-
phorylated FcQRII than C-P, and that C-P more
strongly dissociated Syk-N-SH2 with tyrosine-phos-
phorylated FcQRII than N-P (Figs. 6 and 7). These
¢ndings suggest that Syk-N-SH2 binds to the C-ter-
minal tyrosine residue and Syk-C-SH2 associates
with the N-terminal tyrosine residue on FcQRII
ITAM. This mode of binding is similar to that re-
ported for ZAP/70 to T-cell receptors and that of
Syk to FcO receptors [29,32].
We also found in this study that Syk-NC-SH2
bound more tyrosine-phosphorylated FcQRII than
Syk-N-SH2 or Syk-C-SH2 (3.2-fold as determined
by densitometry) with FcQRII cross-linking. In the
case of FcQRII cross-linking, where two tyrosine res-
idues appear to be phosphorylated, it is most likely
that Syk-NC-SH2 with its two binding sites has a
higher a⁄nity than Syk-N-SH2 or Syk-C-SH2 with
only one binding site. A similar phenomenon is
noted in the binding of Syk SH2 domains with
FcORI [32]. A competitive binding study showed
that the binding a⁄nity of Syk-NC-SH2 to dual ty-
rosine-phosphorylated FcORI is approx. 30 times
higher than that of Syk-C-SH2. The di¡erence in
the Syk-NC-SH2 binding a⁄nity to that of Syk-N-
SH2/Syk-C-SH2 between FcORI and FcQRII (30-fold
vs. 3.2-fold) may be due to the di¡erence in the num-
ber of amino acids inserted between the two tyrosine
residues in the ITAM (7 for FcORI and 12 for
FcQRII) [13^15]. However, in the case of anti-CD9
mAb-induced platelet activation, only one tyrosine
residue of FcQRII appears to be phosphorylated,
and the di¡erence in the binding capacity between
Syk-NC-SH2 and Syk-N/C-SH2 cannot be com-
pletely explained by the duality of the binding sites,
as in the case of FcQRII cross-linking. Crystal struc-
ture studies on Syk and ZAP/70 have revealed an
interaction between the two SH2 domains [29]. The
N-terminal SH2 domain, if expressed in isolation, is
incomplete. This domain may require a contribution
from the neighboring SH2 domain to achieve full
binding capacity. In accord with this, binding studies
with dually tyrosine-phosphorylated peptides showed
that the binding capacity of the N-terminal SH2 is
lower than that of the C-terminal SH2 [29]. How-
ever, since these studies were performed with dual
tyrosine-phosphorylated peptides, to which Syk-
NC-SH2 binds more strongly than Syk-C-SH2, it
has not been clari¢ed whether the binding capacity
of the C-terminal SH2 domain expressed in isolation
is similar to that of Syk-NC-SH2 when only one
tyrosine residue is phosphorylated. Based on our
¢ndings that Syk-NC-SH2 bound more strongly
than Syk-C-SH2 to FcQRII when only the N-terminal
tyrosine residue appeared to be phosphorylated, we
suggest that the C-terminal SH2 domain of Syk, if
expressed in isolation, is also incomplete, and that its
binding capacity to a single phosphorylated tyrosine
residue is lower than that of the two SH2 domains
expressed together.
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